Embryo-Fetal Transfer of Bevacizumab (Avastin) in the Rat Over the Course of Gestation and the Impact of Neonatal Fc Receptor (FcRn) Binding

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 95, Issue 5, 2012, Pages 363-375

  Thorn, Mitchell ^a   Piche Nicholas, Nicole ^a   Stedman, Donald ^a   Davenport, Scott W ^a   Zhang, Ning ^b   Collinge, Mark ^a   Bowman, Christopher J ^a  

^a PFIZER INC   (United States)

^b PERKINELMER INC   (United States)

Author keywords

antibody biodistribution; maternal fetal interactions; monoclonal antibody; neonatal Fc receptor; placenta placentation

Indexed keywords

BEVACIZUMAB; FC RECEPTOR; FLUORESCENT DYE;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DRUG DISTRIBUTION; EMBRYO DEVELOPMENT; EX VIVO STUDY; FEMALE; GESTATIONAL AGE; NONHUMAN; PLACENTAL TRANSFER; PRIORITY JOURNAL; PROTEIN BINDING; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYO, MAMMALIAN; EXTRAEMBRYONIC MEMBRANES; FEMALE; FETUS; HISTOCOMPATIBILITY ANTIGENS CLASS I; MATERNAL-FETAL EXCHANGE; PREGNANCY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, FC;

EID: 84867368252     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.21026     Document Type: Article

References (53)

1. Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. 2007. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol 179(7):4580-4588.
2. Avastin (bevacizumab). 2004. United States, Food and Drug Administration, drug approval report, pharmacology review, available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda
3. Bowman CJ, King LE, Stedman DB. 2012. Embryo-fetal distribution of a biopharmaceutical IgG2 during rat organogenesis. Reprod Toxicol 34:66-72.
4. Brambell FW. 1969. The transmission of immune globulins from the mother to the foetal and newborn young. Proc Nutr Soc 28(1):35-41.
5. Brambell FW, Halliday R. 1956. The route by which passive immunity is transmitted from mother to foetus in the rat. Proc R Soc Lond B 145(919):170-178.
6. Brambell FW, Hemmings WA, Morris IG. 1964. A Theoretical model of gamma-globulin catabolism. Nature 203:1352-1354.
7. Chapman KL, Andrews L, Bajramovic JJ, Baldrick P, Black LE, Bowman CJ, Buckley LA, Coney LA, Couch J, Maggie Dempster A, de Haan L, Jones K, Pullen N, de Boer AS, Sims J, Ian Ragan C. 2012. The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates. Regul Toxicol Pharmacol 62(2):347-354.
8. Chen HX, Gore-Langton RE, Cheson BD. 2001. Clinical trials referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology (Williston Park) 15(8):1017, 1020, 1023-1016.
9. Coe CL, Lubach GR, Izard KM. 1994. Progressive improvement in the transfer of maternal antibody across the order primates. Am J Primatol 32(1):51-55.
10. Dall'Acqua WF, Kiener PA, Wu H. 2006. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281(33):23514-23524.
11. de Rijk EP, van Esch E, Flik G. 2002. Pregnancy dating in the rat: placental morphology and maternal blood parameters. Toxicol Pathol 30(2):271-282.
12. DeSesso JM, Williams AL, Ahuja A, Bowman CJ, Hurtt ME. 2012. The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy. Crit Rev Toxicol 42(3):185-210.
13. Firan M, Bawdon R, Radu C, Ober RJ, Eaken D, Antohe F, Ghetie V, Ward ES. 2001. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol 13(8):993-1002.
14. Fujimoto K, Terao K, Cho F, Honjo S. 1983. The placental transfer of IgG in the cynomolgus monkey. Jpn J Med Sci Biol 36(3):171-176.
15. Garty BZ, Ludomirsky A, Danon YL, Peter JB, Douglas SD. 1994. Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol 1(6):667-669.
16. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. 1996. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26(3):690-696.
17. Halliday R. 1955. Prenatal and postnatal transmission of passive immunity to young rats. Proc R Soc Lond B 144(916):427-430.
18. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vasquez M, Tsurushita N. 2004. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 279(8):6213-6216.
19. Hsei V, Deguzman GG, Nixon A, Gaudreault J. 2002. Complexation of VEGF with bevacizumab decreases VEGF clearance in rats. Pharm Res 19(11):1753-1756.
20. ICH. 2011. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. ICH S6(R1) 2011.
21. Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, Hattori K. 2010. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 23(5):385-392.
22. Israel EJ, Patel VK, Taylor SF, Marshak-Rothstein A, Simister NE. 1995. Requirement for a beta 2-microglobulin-associated Fc receptor for acquisition of maternal IgG by fetal and neonatal mice. J Immunol 154(12):6246-6251.
23. Israel EJ, Simister N, Freiberg E, Caplan A, Walker WA. 1993. Immunoglobulin G binding sites on the human foetal intestine: a possible mechanism for the passive transfer of immunity from mother to infant. Immunology 79(1):77-81.
24. Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE. 1996. Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology 89(4):573-578.
25. Jones EA, Waldmann TA. 1972. The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest 51(11):2916-2927.
26. Junghans RP, Anderson CL. 1996. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93(11):5512-5516.
27. Kim J, Mohanty S, Ganesan LP, Hua K, Jarjoura D, Hayton WL, Robinson JM, Anderson CL. 2009. FcRn in the yolk sac endoderm of mouse is required for IgG transport to fetus. J Immunol 182(5):2583-2589.
28. Kim JK, Firan M, Radu CG, Kim CH, Ghetie V, Ward ES. 1999. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol 29(9):2819-2825.
29. Kim KJ, Fandy TE, Lee VH, Ann DK, Borok Z, Crandall ED. 2004. Net absorption of IgG via FcRn-mediated transcytosis across rat alveolar epithelial cell monolayers. Am J Physiol Lung Cell Mol Physiol 287(3):L616-L622.
30. Kristoffersen EK. 1996. Human placental Fc gamma-binding proteins in the maternofetal transfer of IgG. APMIS Suppl 64:5-36.
31. Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, Lencer WI, Blumberg RS. 2010. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 30(6):777-789.
32. Leach JL, Sedmak DD, Osborne JM, Rahill B, Lairmore MD, Anderson CL. 1996. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol 157(8):3317-3322.
33. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. 1996. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 36(5):248-255.
34. Martin PL, Weinbauer GF. 2010. Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions. Int J Toxicol 29(6):552-568.
35. Martin PL, Breslin W, Rocca M, Wright D, Cavagnaro J. 2009. Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals. Birth Defects Res B 86(3):176-203.
36. Medesan C, Matesoi D, Radu C, Ghetie V, Ward ES. 1997. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol 158(5):2211-2217.
37. Morphis LG, Gitlin D. 1970. Maturation of the maternofoetal transport system for human gamma-globulin in the mouse. Nature 228(5271):573.
38. Ober RJ, Radu CG, Ghetie V, Ward ES. 2001. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13(12):1551-1559.
39. Parr EL, Parr MB. 1985. Localization of immunoglobulins in the mouse uterus, embryo, and placenta during the second half of pregnancy. J Reprod Immunol 8(2-3):153-171.
40. Pentsuk N, van der Laan JW. 2009. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B 86(4):328-344.
41. Roberts DM, Guenthert M, Rodewald R. 1990. Isolation and characterization of the Fc receptor from the fetal yolk sac of the rat. J Cell Biol 111(5 Pt 1):1867-1876.
42. Roopenian DC, Akilesh S. 2007. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7(9):715-725.
43. Ryan AM, Eppler DB, Hagler KE, Bruner RH, Thomford PJ, Hall RL, Shopp GM, O'Neill CA. 1999. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 27(1):78-86.
44. Saji F, Samejima Y, Kamiura S, Koyama M. 1999. Dynamics of immunoglobulins at the feto-maternal interface. Rev Reprod 4(2):81-89.
45. Shah U, Dickinson BL, Blumberg RS, Simister NE, Lencer WI, Walker WA. 2003. Distribution of the IgG Fc receptor, FcRn, in the human fetal intestine. Pediatr Res 53(2):295-301.
46. Simister NE, Mostov KE. 1989. An Fc receptor structurally related to MHC class I antigens. Nature 337(6203):184-187.
47. Simister NE, Rees AR. 1985. Isolation and characterization of an Fc receptor from neonatal rat small intestine. Eur J Immunol 15(7):733-738.
48. Tiwari B, Junghans RP. 2005. Functional analysis of the mouse Fcgrt 5' proximal promoter. Biochim Biophys Acta 1681(2-3):88-98.
49. Vaccaro C, Bawdon R, Wanjie S, Ober RJ, Ward ES. 2006. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci USA 103(49):18709-18714.
50. Vickers TH. 1983. The chronology of somites in rat embryos. Teratology 28(3):457-460.
51. Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, Hochman J, Prueksaritanont T. 2011. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 39(9):1469-1477.
52. Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, Lowman HB. 2009. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 182(12):7663-7671.
53. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. 2010. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28(2):157-159.